NSAID-Associated Lower Gastrointestinal Bleeding: Where Do We Stand?
Francis K.L. Chan
DOI: https://doi.org/10.1016/j.cgh.2012.08.001
IF: 13.576
2012-01-01
Clinical Gastroenterology and Hepatology
Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose aspirin, are the most important cause of nonvariceal upper gastrointestinal (GI) bleeding in many developed countries. Less well known is the fact that NSAIDs can also induce lower GI complications such as bleeding, perforation, stricture, and protein-losing enteropathy. These complications can occur in both the small and large bowel. Unlike NSAID-associated upper GI bleeding, the burden, risk factors, pathogenesis, and prevention of lower GI bleeding associated with NSAID use are poorly understood. This commentary aims to give a brief overview of our current understanding of NSAID-induced small bowel injury and how we should move forward in this field. Little is known about the burden of lower GI events associated with NSAID use. In a population-based study in Taiwan of 1297 patients hospitalized for lower GI adverse events, both oral (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.78–2.85) and parenteral (OR, 5.64; 95% CI, 3.24–9.82) NSAIDs significantly increased risk for lower GI adverse events.1Chang C.H. Lin J.W. Chen H.C. et al.Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan.Gut. 2011; 60: 1372-1378Crossref PubMed Scopus (37) Google Scholar In a population-based Spanish study, there was a decreasing trend in hospitalization due to upper GI events but a significant increase in lower GI events over the past decade.2Lanas A. García-Rodríguez L.A. Polo-Tomás M. et al.Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.Am J Gastroenterol. 2009; 104: 1633-1641Crossref PubMed Scopus (407) Google Scholar The incidence of colonic diverticular bleeding (per 100,000 person-years) increased from 3.3 in 1996 to 8.0 in 2005. This temporal change was associated with an increased use of low-dose aspirin.3Lanas A. García-Rodríguez L.A. Polo-Tomás M. et al.The changing face of hospitalisation due to gastrointestinal bleeding and perforation.Aliment Pharmacol Ther. 2011; 33: 585-591Crossref PubMed Scopus (111) Google Scholar Importantly, they also found that lower GI events had a higher mortality rate (8.8 vs 5.5%), a longer hospitalization, and higher resource utilization than upper GI events.2Lanas A. García-Rodríguez L.A. Polo-Tomás M. et al.Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.Am J Gastroenterol. 2009; 104: 1633-1641Crossref PubMed Scopus (407) Google Scholar Whether these observations can be generalized to other populations is uncertain. Even more unclear are the risk factors for NSAID-associated lower GI events. Recent data suggest that increasing age, a history of GI intolerance, high C-reactive protein levels, and Helicobacter pylori infection increase the likelihood of significant occult blood loss from the small bowel.4Lanas A. Goldstein J.L. Chan F.K. et al.Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).Aliment Pharmacol Ther. 2012; 36: 485-492Crossref PubMed Scopus (32) Google Scholar NSAIDs probably damage the small bowel through cyclo-oxygenase (COX)-dependent and COX-independent pathways. COX-dependent pathway is mediated through inhibition of prostaglandin synthesis, leading to disruption of the small bowel mucosal barrier. However, the COX-inhibition may not play a major role in NSAID-induced small bowel injury.5Whittle B.J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat.Gastroenterology. 1981; 80: 94-98Abstract Full Text PDF PubMed Scopus (419) Google Scholar There is increasing evidence that COX-independent pathways contribute to NSAID-induced small bowel injury. Specifically, NSAIDs cause mitochondrial dysfunction.6Somasundaram S. Rafi S. Hayllar J. et al.Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine.Gut. 1997; 41: 344-353Crossref PubMed Scopus (282) Google Scholar The latter increases intestinal permeability, such that other noxious agents including bile and enterobacteria can further damage the small bowel. NSAIDs with significant enterohepatic circulation are associated with more severe distal ileal damage.7Seitz S. Boelsterli U.A. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats.Gastroenterology. 1998; 115: 1476-1482Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar Overgrowth of gram negative bacteria plays an important role in NSAID-induced small bowel damage. Antibiotics active against gram-negative bacteria have been shown to reduce small bowel damage induced by indomethacin in rats.8Konaka A. Kato S. Tanaka A. et al.Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats.Pharmacol Res. 1999; 40: 517-524Crossref PubMed Scopus (117) Google Scholar Regardless of the noxious stimulus, neutrophil activation mediated by Toll-like receptor 4 and tumor necrosis factor appears to be the final common pathway in NSAID-induced small bowel injury.9Watanabe T. Higuchi K. Kobata A. et al.Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent.Gut. 2008; 57: 181-187Crossref PubMed Scopus (206) Google Scholar While acid suppressive drugs such as proton pump inhibitors (PPIs) are well established in the management of gastroduodenal ulcers associated with NSAID use, there is no proven treatment for NSAID-induced injury beyond the Ligament of Treitz. A number of potential therapeutic agents have been evaluated. Because injury in the small bowel is not acid dependent, PPIs cannot prevent NSAID-induced small bowel injury. Recent animal data showed that PPIs may actually exacerbate small bowel injury associated with nonselective and COX-2 selective NSAIDs through disturbance of small bowel flora (dysbiosis). Interestingly, small bowel injury could be alleviated by adding a suspension of bowel flora to rats receiving NSAIDs and PPIs.10Wallace J.L. Syer S. Denou E. et al.Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.Gastroenterology. 2011; 141: 1314-1322Abstract Full Text Full Text PDF PubMed Scopus (377) Google Scholar This finding, if confirmed in clinical studies, will have important implications on how we should use PPI prophylaxis. Short-term studies using capsule endoscopy have consistently shown that celecoxib caused fewer small bowel mucosal breaks compared to nonselective NSAIDs plus a PPI.11Goldstein J.L. Eisen G.M. Lewis B. et al.Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.Clin Gastroenterol Hepatol. 2005; 3: 133-141Abstract Full Text Full Text PDF PubMed Scopus (592) Google Scholar, 12Goldstein J.L. Eisen G.M. Lewis B. et al.Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy.Aliment Pharmacol Ther. 2007; 25: 1211-1222Crossref PubMed Scopus (158) Google Scholar In a large-scale, double-blind, randomized trial, anemia due to presumed small bowel occult blood loss was 5 times lower in patients receiving celecoxib than in patients receiving diclofenac plus a PPI.13Chan F.K. Lanas A. Scheiman J. et al.Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.Lancet. 2010; 376: 173-179Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar However, there is no evidence that other COX-2 selective NSAIDs such as etoricoxib have less small bowel injury than nonselective NSAIDs. Thus, the relative small-bowel sparing effect of celecoxib is probably related to its physicochemical properties rather than COX-2 selectivity. Prostagladins contribute to maintaining mucosal integrity of the entire GI tract. Misoprostol is a prostaglandin analog. A short-term randomized trial of healthy volunteers showed that misoprostol co-therapy significantly reduced NSAID-induced small bowel lesions compared to the group treated with omeprazole.14Fujimori S. Seo T. Gudis K. et al.Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy.Gastrointest Endosc. 2009; 69: 1339-1346Abstract Full Text Full Text PDF PubMed Scopus (129) Google Scholar A case series reported that misoprostol healed small bowel mucosal breaks associated with enteric-coated aspirin.15Watanabe T. Sugimori S. Kameda N. et al.Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study.Clin Gastroenterol Hepatol. 2008; 6: 1279-1282Abstract Full Text Full Text PDF PubMed Scopus (163) Google Scholar Long-term clinical outcome studies are required to evaluate the efficacy and tolerability of misoprostol in preventing small bowel complications associated with NSAID use. A number of mucoprotective agents have been developed and are widely used in Asian countries such as Japan, Korea, and China. Better known examples include sucralfate, rebamipide, geranylgeranylacetone, teprenone, and gefarnate. Various mechanisms have been proposed, including suppression of inflammation and stimulation of growth factors, heat shock proteins, nitric oxide, and prostaglandins. However, only limited short-term prospective studies with conflicting results are available in the literature.16Shiotani A. Haruma K. Nishi R. et al.Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin Low-dose aspirin-induced small bowel damage.Scand J Gastroenterol. 2010; 45: 292-298Crossref PubMed Scopus (61) Google Scholar, 17Fujimori S. Takahashi Y. Gudis K. et al.Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy.J Gastroenterol. 2011; 46: 57-64Crossref PubMed Scopus (63) Google Scholar Despite the extensive use of these agents, their clinical efficacy remains uncertain. Short-term randomized trials showed that a probiotic mixture (VSL#3) and Lactobacillus casei reduced NSAID-associated small bowel mucosal injury and fecal calprotectin concentration, respectively.18Endo H. Higurashi T. Hosono K. et al.Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study.J Gastroenterol. 2011; 46: 894-905Crossref PubMed Scopus (94) Google Scholar, 19Montalto M. Gallo A. Curigliano V. et al.Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy—a randomized, double-blind, cross-over, placebo-controlled study.Aliment Pharmacol Ther. 2010; 32: 209-214Crossref PubMed Scopus (69) Google Scholar Long-term clinical data are not yet available. Lower GI complications associated with NSAID use, in particular, obscure bleeding from the small bowel, were largely under-recognized in the past. With increasing use of NSAIDs and low-dose aspirin, the burden of lower GI complications is expected to increase. Current evidence suggests that the mechanisms leading to small bowel injury with NSAID use are distinct from those of the upper GI tract. Prophylactic treatment with PPIs cannot prevent and may even aggravate small bowel injury. The benefit of COX-2 inhibitors, misoprostol, and probiotics needs further evaluation. There is an urgent, unmet need of defining the risk factors and preventive strategies for this emerging clinical problem. In the future, combination therapy may be needed to protect the entire GI tract in high-risk patients on NSAIDs. Unfortunately, these important clinical questions are unlikely to be priorities of pharmaceutical companies.